B I E N V E N I D O S
-
-
Nuestras Páginas
- - Acerca de Strategic Consulting
- - Strategic Consulting Videos
- Apple mira hacia los clientes
- Bienvenidos / Welcome
- Colesterol y la danza de los millones
- De la reglamentación para la venta de medicamentos
- El intento de Microsoft por comprar Yahoo!
- En apoyo a las Fuerzas Armadas de México
- Impact on Biologics Lifecycle management. Por Bob Ward.
- Influenza A (H1N1) en México
- Podcasts
- Reiniciamos con nuestro Blog.
- Sobre la nueva imagen de Correos de México (antes SEPOMEX)
- Sobre Tabaquismo y Ley Antitabaco
- Strategic Consulting en los medios impresos
- Strategic Consulting en Medios Electrónicos
- Test Video
-
Artículos o Podcasts recientes
Nuestros Archivos
- September 2010 (1)
- August 2010 (3)
- July 2010 (3)
- June 2010 (3)
- May 2010 (4)
- April 2010 (3)
- March 2010 (2)
- February 2010 (2)
- January 2010 (6)
- December 2009 (7)
- November 2009 (4)
- October 2009 (4)
- September 2009 (9)
- August 2009 (9)
- July 2009 (10)
- June 2009 (4)
- May 2009 (16)
- April 2009 (22)
- March 2009 (17)
- February 2009 (20)
- January 2009 (19)
- December 2008 (14)
- November 2008 (5)
- October 2008 (14)
- September 2008 (3)
- August 2008 (8)
- July 2008 (5)
- June 2008 (10)
- May 2008 (21)
- April 2008 (21)
- March 2008 (12)
- February 2008 (10)
- January 2008 (15)
- December 2007 (12)
- November 2007 (13)
- October 2007 (21)
- September 2007 (7)
- August 2006 (3)
- June 2006 (4)
- May 2006 (7)
- April 2006 (9)
Tag Archives: Hip
FDA Advisory Committee Briefing hits Bayer’s Xarelto® badly.
By Xavier Tello One of the most desired markets of the pharmaceutical business has been the clotting-prevention. Ever since the first use of systemic heparin and the late surging of the low molecular weight heparins (LMWH) such as Lovenox® (enoxaparin), … Continue reading
Posted in Alta Dirección, Mercadotecnia, Salud, Ventas
Tagged Arixtra, Bayer, Cadera, Deep Venous Thrombosis, Enoxaparin, FDA, Fondaparinux, Fraxiparine, Hip, Johnson & Johnson, Knee, Lovenox, Nadroparin, Pulmonary thromboembolism, Rivaroxavan, Rodilla, Sanofi Aventis, Tromboembolia pulmonar, Trombosis Venosa Profunda, Xarelto
Leave a comment
